Myocardial ischemia/reperfusion and heart failure are the major cardiac
conditions in which an imbalance between oxidative stress and anti-oxidant
mechanisms is observed. The myocardium has endogenous reducing mechanisms,
including the thioredoxin (Trx) and glutathione systems, that act to scavenge
reactive oxygen species (ROS) and reduce oxidized proteins. The Trx system
consists of Trx, Trx reductase (TrxR), and an electron donor, NADPH, where Trx
is maintained in a reduced state in the presence of TrxR and NADPH. Trx1, a
major isoform of Trx, is abundantly expressed in the heart and exerts its
oxidoreductase activity through conserved Cys32 and Cys35, reducing oxidized
proteins through thiol disulfide exchange reactions. In this review, we will
focus on molecular targets of Trx1 in the heart, including transcription
factors, microRNAs, histone deactylases, and protein kinases. We will then
discuss how Trx1 regulates the functions of its targets, thereby affecting the
extent of myocardial injury caused by myocardial ischemia/reperfusion and the
progression of heart failure.